TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06469333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye movements (EM)
Description: The participant focuses on the intrusive thought and visually follows the horizontal movement of a white dot (Ø 1 cm) on the black computer screen 8 times for 24 seconds.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye movements (EM)
Description: The participant focuses on the intrusive thought and visually follows the horizontal movement of a white dot (Ø 1 cm) on the black computer screen 8 times for 24 seconds.
Study: NCT05449145

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 1st week: Vitamin D 82285.71 IU per day (total dose: 576000IU per week); 2th to 4th week: Vitamin D 41142.86 IU per day (total dose: 288000IU per week); 5th to 8th week: fish oil 2 capsules per day（each capsule contains EPA 900mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non-Vitamin D
Description: 1st week: 95% MCT oil 5.71 ml per day (total dose: 40 ml per week); 2th to 4th week: 95% MCT oil 2.86 ml per day (total dose: 20 ml per week); 5th to 8th week: fish oil 2 capsules per day（each capsule contains EPA 900mg)
Study: NCT06068803

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone drink
Description: Participants will consume three daily ketone monoester (KME) drinks (0.282g KME/kg body weight/ serving) for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume three daily taste-matched calorie-free placebo drinks for 4 weeks.
Study: NCT05791552

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Collection of nasal secretion
Description: Standardized collection of nasal secretion in the vicinity of the olfactory cleft

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Collection of nasal secretion
Description: Standardized collection of nasal secretion in the vicinity of the olfactory cleft
Study: NCT06469333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye movements (EM)
Description: The participant focuses on the intrusive thought and visually follows the horizontal movement of a white dot (Ø 1 cm) on the black computer screen 8 times for 24 seconds.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory stimulations
Description: The participant focuses on the intrusive thoughts and hears the auditory beeps through the headphones provided 8 times for 24 seconds.
Study: NCT06156397

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physiotherapy Exercise Group
Description: At the beginning of the treatment, breathing exercises, upper extremity pumping exercises, scar tissue massage and flexion movements up to 90 degrees will be applied for the first 2 weeks. 2-6. Between weeks, pendulum exercise, shoulder rotation, lifting overhead with clasped hands while sitting and lying down, wand exercise, snow angels, clock on the wall exercise, m. Pectoralis minor and major stretching, standing trunk rotation, and scapulo-thoracic joint stabilization exercises will be applied. 6-8. In the following weeks, in addition to the previous exercises, strengthening exercises will be applied in all directions with theraband and weights. Exercises will start with 2 sets of 5-10 repetitions and progress to 10-15 repetitions. Exercises will be performed for 45 minutes, twice a week, for a total of 12 sessions, for a total of 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation Based Supervised Exercise Group
Description: Exercises will be performed for 45 minutes, twice a week, for a total of 12 sessions, for a total of 6 weeks. In the telerehabilitation group, breathing exercises, upper extremity pumping exercises, scar tissue massage and flexion movements up to 90 degrees will be applied for the first 2 weeks at the beginning of the treatment, through a meeting with the patients via zoom application. 2-6. Between weeks, pendulum exercise, shoulder rotation, lifting overhead with clasped hands while sitting and lying down, wand exercise, snow angels, clock on the wall exercise, m. Pectoralis minor and major stretching, standing trunk rotation, and scapulo-thoracic joint stabilization exercises will be applied. 6-8. In the following weeks, in addition to the previous exercises, strengthening exercises will be applied in all directions with theraband and weights.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Application Supported Exercise Group
Description: With the videos uploaded to the Becure application, breathing exercises, upper extremity pumping exercises, scar tissue massage and flexion movements up to 90 degrees will be applied in the first 2 weeks. 2-6. Between weeks, pendulum exercise, shoulder rotation, lifting overhead with clasped hands while sitting and lying down, wand exercise, snow angels, clock on the wall exercise, m. Pectoralis minor and major stretching, standing trunk rotation, and scapulo-thoracic joint stabilization exercises will be applied. 6-8. Between weeks, in addition to the previous exercises, strengthening exercises will be applied in all directions with theraband and weight. Exercises will start with 2 sets of 5-10 repetitions and progress to 10-15 repetitions.
Study: NCT06350981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: 20 mL of EXPAREL 266mg mixed with 10 mL of 0.25% bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Standard of care will consist of 0.25% Bupivacaine HCl TLIP injection 30mL
Study: NCT04708704

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Erythrosine, prepared in drinking water (0.69 mg/kg bw/day)
Description: Erythrosine will be obtained from Roxy \& Rich Inc. (Intense Water-Soluble Food Colorant - Pink), which is certified to be edible and complies with US FDA, Health Canada, and European food safety standards. The erythrosine will be prepared in 500 mL of drinking water and participants will received single daily doses for 14 days. We will use a targeted dose of 0.69 mg/kg bw.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SODIS-treated erythrosine, prepared in drinking water (0.69 mg/kg bw/day)
Description: Erythrosine will be SODIS-treated to produce photobleached erythrosine. Transparent 500 mL polyethylene terephthalate (PET) plastic water bottles will be commercially purchased (Kirkland Signature Purified Water). All branding information and labeling will be removed from the bottles. Water bottles will be dosed with \~41 mg erythrosine (0.69 mg/kg bw) using an erythrosine stock solution (8.2 g/L) and will be shaken to mix. The erythrosine-dosed bottles will be placed on a metal shelf and exposed to natural sunlight on the roof of Yale Engineering. Sunlight exposure will be conducted until the absorbance value of erythrosine at the absorption maximum of 526 nm falls below 0.05 above baseline, as measured by ultraviolet-visible spectroscopy. The water bottles containing photobleached erythrosine will be stored under refrigeration in the dark until consumption by participants.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iodine, prepared in drinking water 0.075 mg/kg bw/day)
Description: Iodine used in the study will be in the form of FCC-grade potassium iodide, which will be obtained from VWR. FCC grade potassium iodide meets the requirements set by the Food Chemical Codex and is suitable for all applications in foods and beverages. Iodine (control exposure) will be prepared in 500 mL of drinking water and participants will received single daily doses for 14 days. We will use a targeted dose of 0.75 mg/kg bw.
Study: NCT05719428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DRUID AI Program
Description: Patients will begin single agent therapy within 4 weeks of enrolment and continue until disease progression, maximum safe cumulative dose reached (where applicable, per standard institution practice) or unacceptable toxicity as per physician's discretion.
Study: NCT05574439

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TCOC treatment
Description: The TCOC protocol is a chronic care, family-based and multidisciplinary childhood obesity treatment program involving behavior-changing techniques, based on current guidelines for best-practice and authoritative recommendations involving a multidisciplinary tertiary team of health care professionals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TCOC treatment
Description: The TCOC protocol is a chronic care, family-based and multidisciplinary childhood obesity treatment program involving behavior-changing techniques, based on current guidelines for best-practice and authoritative recommendations involving a multidisciplinary tertiary team of health care professionals.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TCOC treatment
Description: The TCOC protocol is a chronic care, family-based and multidisciplinary childhood obesity treatment program involving behavior-changing techniques, based on current guidelines for best-practice and authoritative recommendations involving a multidisciplinary tertiary team of health care professionals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TCOC treatment
Description: The TCOC protocol is a chronic care, family-based and multidisciplinary childhood obesity treatment program involving behavior-changing techniques, based on current guidelines for best-practice and authoritative recommendations involving a multidisciplinary tertiary team of health care professionals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 3 mg/ml
Description: Participants will be instructed to initiate at 0.24 mg SC once weekly for 4 weeks, and in 4 week intervals, increase the dose until a dose of 2.4 mg is reached. In case of prolonged side effects the dose may be adjusted to lower than 2.4mg/week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 3 mg/ml
Description: Participants will be instructed to initiate at 0.24 mg SC once weekly for 4 weeks, and in 4 week intervals, increase the dose until a dose of 2.4 mg is reached. In case of prolonged side effects the dose may be adjusted to lower than 2.4mg/week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Semaglutide 3 mg/ml)
Description: Participants will be instructed to initiate at 0.24 mg SC once weekly for 4 weeks, and in 4 week intervals, increase the dose until a dose of 2.4 mg is reached. In case of prolonged side effects the dose may be adjusted to lower than 2.4mg/week.
Study: NCT06469333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory stimulations
Description: The participant focuses on the intrusive thoughts and hears the auditory beeps through the headphones provided 8 times for 24 seconds.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tactile stimulations
Description: The participant focuses on the intrusive thought and applies tactile self-stimulation 8 times for 24 seconds.
Study: NCT05574439

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Semaglutide 3 mg/ml)
Description: Participants will be instructed to initiate at 0.24 mg SC once weekly for 4 weeks, and in 4 week intervals, increase the dose until a dose of 2.4 mg is reached. In case of prolonged side effects the dose may be adjusted to lower than 2.4mg/week.
Study: NCT05903976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor de-escalation
Description: Comparing, in patients at High Bleeding Risk (HBR) after a recent Acute Coronary Syndrome (ACS), continuation of full-dose potent P2Y12 inhibitor with a P2Y12i de-escalation strategy transitioning to clopidogrel 75mg, prasugrel 5mg or ticagrelor 60mg/bid.
Study: NCT05013359

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study: NCT06526988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPIC-HF Patient-facing Tool
Description: A brief, animated video designed to engage and activate patients around their HFrEF medication prescribing sent prior to routine cardiology clinic visit, accompanied by a one-page HeartMeds Guide checklist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPIC-HF Patient-facing Tool
Description: A brief, animated video designed to engage and activate patients around their HFrEF medication prescribing sent prior to routine cardiology clinic visit, accompanied by a one-page HeartMeds Guide checklist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROMPT-HF Clinician-facing Alert
Description: A best practice alert will appear for each eligible patient upon opening of the order entry screen in the patient's medical record. This alerts the provider of the presence of HFrEF, notes the patient's current LVEF and current evidence-based medications, and gives access to an order set with recommended evidence-based, guideline-recommended, and FDA- approved therapies for patients with HFrEF. Providers will also have access to a link to best available guideline recommended information regarding treatment of heart failure to allow further education if desired by the provider. The alerts will also clearly state the expected monitoring and follow-up required for prescriptions of these medications.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROMPT-HF Clinician-facing Alert
Description: A best practice alert will appear for each eligible patient upon opening of the order entry screen in the patient's medical record. This alerts the provider of the presence of HFrEF, notes the patient's current LVEF and current evidence-based medications, and gives access to an order set with recommended evidence-based, guideline-recommended, and FDA- approved therapies for patients with HFrEF. Providers will also have access to a link to best available guideline recommended information regarding treatment of heart failure to allow further education if desired by the provider. The alerts will also clearly state the expected monitoring and follow-up required for prescriptions of these medications.
Study: NCT05167162

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapeutic intervention
Description: Participants received one session per week, until a total of 20 sessions were completed: Group 1 (n=20) received the muscle compression treatment. Group 2 (n=20) received the manual massage treatment. Group 3 (n=20) received the hydrotherapy treatment and group 4 (n=20) received the active recovery treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapeutic intervention
Description: Participants received one session per week, until a total of 20 sessions were completed: Group 1 (n=20) received the muscle compression treatment. Group 2 (n=20) received the manual massage treatment. Group 3 (n=20) received the hydrotherapy treatment and group 4 (n=20) received the active recovery treatment.
Study: NCT05903976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P2Y12 inhibitor de-escalation
Description: Comparing, in patients at High Bleeding Risk (HBR) after a recent Acute Coronary Syndrome (ACS), continuation of full-dose potent P2Y12 inhibitor with a P2Y12i de-escalation strategy transitioning to clopidogrel 75mg, prasugrel 5mg or ticagrelor 60mg/bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor de-escalation
Description: Comparing, in patients at High Bleeding Risk (HBR) after a recent Acute Coronary Syndrome (ACS), continuation of full-dose potent P2Y12 inhibitor with a P2Y12i de-escalation strategy transitioning to clopidogrel 75mg, prasugrel 5mg or ticagrelor 60mg/bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor de-escalation
Description: Comparing, in patients at High Bleeding Risk (HBR) after a recent Acute Coronary Syndrome (ACS), continuation of full-dose potent P2Y12 inhibitor with a P2Y12i de-escalation strategy transitioning to clopidogrel 75mg, prasugrel 5mg or ticagrelor 60mg/bid.
Study: NCT06137794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of I-Anticoagulation to make the decision and manage patients
Description: I-Anticoagulation will offer a flexible and efficient communication platform for healthcare professionals and AF patients. The tool is composed of two modules: an anticoagulation decision support system and a full-process patient management system.
Study: NCT05468866

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Genotyping of rs1980422-related single-nucleotide polymorphisms by real time PCR
Description: detection of rs1980422-related single-nucleotide polymorphisms and percentage of (CD3,CD4,CD28) by immunophenotyping

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Genotyping of rs1980422-related single-nucleotide polymorphisms by real time PCR
Description: detection of rs1980422-related single-nucleotide polymorphisms and percentage of (CD3,CD4,CD28) by immunophenotyping
Study: NCT05706441

Intervention type: OTHER
Intervention: Point-of-Care Ultrasound
Description: Ultrasonographic scans of the lung and right hemidiaphragm were acquired after 30 min from the beginning of the SBT, or immediately before reconnecting the patient to the ventilator in the case of SBT failure occurring before
Study: NCT04584437

Intervention type: OTHER
Group type: OTHER
Intervention: Infrared Energy and Dietary Supplement
Description: Infrared Energy with a wavelength of 5 - 20 microns. Multivitamins and minerals including Vitamin C Supplements.
Study: NCT06230445

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UHealth digital therapeutic
Description: UHealth digital therapeutic is an application that patients can report their symptoms. If the contents that patients fill in reach the threshold, UHealth application will automatic report to doctor and the doctor will give medical advisement through UHealth digital therapeutic application.
Study: NCT05832203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling on planetary health diet with calorie restriction
Description: Counselling on planetary healthy diet, calorie restriction diet, and healthy lifestyle through mobile application

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Counseling on balanced nutrition diet with calorie restriction
Description: Counselling on balanced nutrition diet, calorie restriction diet, and healthy lifestyle materials through mobile app
Study: NCT04975178

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTBVAC
Description: MTBVAC is a novel TB vaccine candidate based on an attenuated M. tuberculosis clinical isolate of the Euro-American lineage. Attenuation is based on two independent, stable genetic deletions of the genes phoP and fadD26 coding for two major virulence factors, the transcription factor PhoP and the cell-wall lipids PDIM, respectively. We hypothesize that MTBVAC will provide improved protection, as individuals latently infected with live M.tuberculosis have an 80% lower chance of developing TB, and as MTBVAC contains most of the genes deleted from BCG and presents a wider collection of antigens to the host immune system. Preclinical studies in different animal models indicated that MTBVAC is safe and is able to induce an improved protection compared to BCG.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: BCG is a live attenuated M. bovis strain developed 100 years ago and is used as a preventive vaccine against tuberculosis. It is administered at birth.
Study: NCT05167162

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data Analysis
Description: The usual descriptive parameters (mean and standard deviation) of the sample were calculated. The distribution and analysis of the other data were performed by means of a nonparametric test (Mann-Whitney U test) comparing the groups. A confidence level of 95% was established, considering a value of p\<0.05 as statistically significant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data Analysis
Description: The usual descriptive parameters (mean and standard deviation) of the sample were calculated. The distribution and analysis of the other data were performed by means of a nonparametric test (Mann-Whitney U test) comparing the groups. A confidence level of 95% was established, considering a value of p\<0.05 as statistically significant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data Analysis
Description: The usual descriptive parameters (mean and standard deviation) of the sample were calculated. The distribution and analysis of the other data were performed by means of a nonparametric test (Mann-Whitney U test) comparing the groups. A confidence level of 95% was established, considering a value of p\<0.05 as statistically significant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data Analysis
Description: The usual descriptive parameters (mean and standard deviation) of the sample were calculated. The distribution and analysis of the other data were performed by means of a nonparametric test (Mann-Whitney U test) comparing the groups. A confidence level of 95% was established, considering a value of p\<0.05 as statistically significant.
Study: NCT05804669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRN04894
Description: CRN04894 is an orally active investigational agent which antagonizes the action of ACTH at its receptor administered as oral tablets.
Study: NCT06000865

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Action video game training
Description: 20 sessions of AVG over 10 weeks (45 minutes per session, 2 sessions per week)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional physical training
Description: 20 sessions of physical training over 10 weeks (45 minutes per session, 2 sessions per week)
Study: NCT05978401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-012+GLS-010
Description: Two dose levels will be evaluated for GLS-012+GLS-010 administered. GLS-012+GLS-010 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-012+GLS-010
Description: Target dose levels will be evaluated for GLS-012+GLS-010 administered. GLS-012+GLS-010 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-012+GLS-010+pemetrexed+carboplatin
Description: GLS-012+GLS-010 will be given via IV infusion on Day 1 of each 21-day cycle in combination with pemetrexed and carboplatin. Combination treatment will be administered 4\~6 cycles.GLS-012+GLS-010/GLS-010 may continue until disease progression or loss of clinical benefit.